Background:

Incidence rates of epithelial ovarian cancer (EOC) vary across racial/ethnic groups, yet little is known about the impact of hormone-related EOC risk factors in non-Whites.

Methods:

Among 91,625 female Multiethnic Cohort Study participants, 155 incident EOC cases were diagnosed in Whites, 93 in African Americans, 57 in Native Hawaiians, 161 in Japanese Americans, and 141 in Latinas. We used Cox proportional hazards regression models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between race/ethnicity and EOC risk and between hormone-related factors and EOC risk across racial/ethnic groups.

Results:

Compared with Whites, African Americans and Japanese Americans had a lower multivariable-adjusted EOC risk; Native Hawaiians had a suggestive higher risk. Parity and oral contraceptive (OC) use were inversely associated with EOC risk (Pint race/ethnicity ≥ 0.43); associations were strongest among Japanese Americans (e.g., ≥4 vs. 0 children; HR = 0.45; CI, 0.26–0.79). Age at natural menopause and postmenopausal hormone (PMH) use were not associated with EOC risk in the overall population, but were positively associated with risk in Latinas (e.g., ≥5 years vs. never PMH use; HR = 2.13; CI, 1.30–3.49).

Conclusions:

We observed strong associations with EOC risk for parity and OC use in Japanese Americans and PMH use and age at natural menopause in Latinas. However, differences in EOC risk among racial/ethnic groups were not fully explained by established hormone-related risk factors.

Impact:

Our study indicates there are racial/ethnic differences in EOC risk and risk factors, and could help improve prevention strategies for non-White women.

Ovarian cancer incidence differs substantially by race/ethnicity, with the highest age-standardized rates (per 100,000 in 2010–2014) in the United States observed in non-Hispanic White (hereafter referred to as White) women (12.0), intermediate rates in Hispanic women (10.3), and lowest rates among African American (9.4) and Asian/Pacific Islander women (9.2; ref. 1). Notably, ovarian cancer incidence rates among Native Hawaiian women (11.8 per 100,000 in 2008–2012) are comparable with the high rates observed for White women in the United States and in Hawaii (12.0; refs. 1, 2).

The most common type of malignant ovarian cancer is epithelial ovarian cancer (EOC), which is a heterogeneous disease with at least four major histologic subtypes: serous, mucinous, endometrioid, and clear cell. Many of the known EOC risk factors are related to reproduction (3–5); however, few studies have evaluated EOC risk factors among non-White women (6–10). To our knowledge five case–control studies have assessed EOC risk factors in African Americans (7–10), and one in Latinas (7). In addition, the largest study to date pooled data from 12 Ovarian Cancer Association Consortium (OCAC) case–control studies based in the United States, Australia, and Canada (including data from refs. 7, 9), and included 911 African American, 662 Asian/Pacific Islander, 433 Latina, and 8,918 White cases (6). Peres and colleagues (6) reported a generally similar direction of associations across racial/ethnic groups, including oral contraceptive (OC) use, although some differences were seen: family history of breast and/or ovarian cancer was most strongly associated with increased EOC risk among African Americans and Latinas; positive associations of hysterectomy and endometriosis with EOC risk were strongest in African Americans; and Asian/Pacific Islanders had the strongest decrease in EOC risk with higher parity. Limitations of the OCAC study were the retrospective design and their inability to separate Asians and Pacific Islanders. An earlier EOC case–control study included Native Hawaiian women (in addition to Japanese Americans and Whites from Hawaii), but results were not reported separately for these racial/ethnic groups (11).

We analyzed data from the Multiethnic Cohort (MEC) Study, an ethnically diverse cohort including Whites, African Americans, Native Hawaiians, Japanese Americans, and Latinas. This study of EOC risk factors provides new insights to understand the unique pathogenesis of EOC among these understudied minority groups, which could be used to inform potential avenues for prevention among racial/ethnically diverse populations.

Study population

The design of the MEC Study has been detailed previously (12, 13). Briefly, between 1993 and 1996 over 215,000 men and women aged 45 to 75 years completed a mailed baseline questionnaire including questions on lifestyle and reproductive factors, hormone use, anthropometrics, and race/ethnicity. Participants were followed up via the Surveillance, Epidemiology, and End Results (SEER) cancer registries for Hawaii and California for diagnosis of cancer and information on tumor histology and stage was obtained. Incident invasive EOC was defined as ovarian, fallopian tube, or primary peritoneal cancer using International Classification of Diseases for Oncology 3rd revision (ICD-O3) codes C56.9, C57.0, and C48. ICD-O3 morphology codes were used to exclude nonepithelial tumors and to define histologic subtypes (Supplementary Table S1). Vital status was determined by linkage to state death files and the National Death Index. The end of follow-up was defined as the date of diagnosis of incident EOC, date of death, or date of complete case and death ascertainment (December 31, 2014), whichever occurred first. From the 110,712 women from five main racial/ethnic groups in the MEC Study (White, African American, Native Hawaiian, Japanese American, and Latina), we excluded 227 participants diagnosed with EOC prior to cohort entry (identified via tumor registry or self-reported on the baseline questionnaire), 18,686 participants who self-reported a bilateral or unspecified oophorectomy at baseline, 61 participants with <1 year of follow-up, 57 participants missing extensive baseline questionnaire information (OC use, number of children, and ages at menarche and first birth), and 56 EOC cases with nonepithelial tumors, leaving 91,625 participants in our study.

Exposures and covariates

Exposures of interest were: parity (no, yes); number of children (0, 1, 2, 3, ≥4); age at menarche (<13, 13–14, ≥15 years); OC use [never, ever (≥1 month of use) and OC duration (never, <5, ≥5 years)]; age at natural menopause (<45, 45–49, 50–54, ≥55 years; in postmenopausal women reporting a natural menopause); use of postmenopausal hormones (PMH) containing estrogen among postmenopausal women [never, ever, and PMH duration (never, <5, ≥5 years)]; body mass index (BMI; <25, 25–29, ≥30 kg/m2); diabetes (no, yes); smoking status (never, ever); and family history of breast and/or ovarian cancer in a first-degree relative (no, yes). The cumulative duration of ovulatory years is a composite measure of ovarian cancer risk factors, estimating the number of natural menstrual cycles a woman experiences during her lifespan. It was calculated as the number of years between age at menarche and either age at baseline (if premenopausal) or age at natural menopause (if postmenopausal), minus the duration of OC use and time spent pregnant (number of children*0.75 years); postmenopausal women with a surgical menopause or unknown type of menopause were excluded.

Statistical analysis

We used Cox proportional hazards regression models, with the time between study entry and exit (end of follow-up) as the time scale, to calculate hazard ratios (HR) and 95% confidence intervals (CI) for EOC risk. Multivariable models were adjusted for important confounders that were selected a priori; age, menopausal status at baseline, ever OC use, and number of children; models in the full population were additionally adjusted for race/ethnicity. We tested additional adjustment for age at first birth (in parous women; <21, 21–24, ≥25 years), age at menarche (<13, 13–14, ≥15 years), age at natural menopause (among postmenopausal women reporting a natural menopause; <45, 45–49, 50–54, ≥55 years), PMH use (among postmenopausal women; no, yes), hysterectomy (no, yes, missing), BMI (<25, 25–29.9, ≥30 kg/m2), diabetes (no, yes), family history of breast and/or ovarian cancer (no, yes, missing) and, years of education (12th grade or less, vocational training or some college education, college graduate or higher). These factors did not impact the results (<10% HR change in all models) and were not included as covariates in the final models stratified for race/ethnicity (14). For models with race/ethnicity as the exposure we, in addition to the multivariable adjusted model adjusting for a priori selected covariates, calculated a fully adjusted model accounting for all EOC risk factors available in the MEC Study. Missing data in exposure variables were excluded from models. For all covariates (except family history of breast and/or ovarian cancer) less than 5% of data were missing, which were set to the largest race/ethnicity–specific category. Models that included family history (8% missing data) as a covariate included a separate missing category. P values for trend were calculated using continuous variables when available. Interactions between race/ethnicity and the exposures of interest were evaluated by comparing multivariable models with and excluding multiplicative interaction terms using likelihood ratio tests. The proportional hazards assumption was assessed using Schoenfeld residuals and no violation was observed. Descriptive analyses were age-standardized (15).

We carried out sensitivity analyses restricting to women who were postmenopausal at baseline (83% of participants) and restricting the outcome to serous/carcinoma not otherwise specified (hereafter referred to as serous; 74% of cases) by censoring nonserous histologic subtypes. A 95% CI excluding one or, for test for interaction, a two tailed P < 0.05 was considered statistically significant. Analyses were performed using SAS 9.4.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board at the University of Hawaii (Honolulu, HI). The Multiethnic Cohort Study was approved by the Institutional Review Boards at the University of Hawaii and the University of Southern California.

The median age at cohort entry in the overall study population was 60 years (interquartile range, 52–67); Native Hawaiians were the youngest (54 years) and Japanese Americans the oldest (62 years; Table 1). Comparing age-standardized reproductive characteristics across five racial/ethnic groups, Native Hawaiians and Latinas had higher parity (≥50% had ≥4 children compared with ≤35% of African Americans, Whites, and Japanese Americans). Ever use of OCs was highest in Whites (50%), intermediate in African Americans (44%), and lowest in Native Hawaiians, Japanese Americans, and Latinas (≤36%). PMH use was higher in Whites and Japanese Americans (≥51% ever users) and lower in African Americans, Native Hawaiians, and Latinas (≤39% ever users). The proportion of women with an obese BMI (≥30 kg/m2) was highest in African Americans (37%) and Native Hawaiians (32%), intermediate in Latinas (27%) and Whites (18%), and lowest in Japanese Americans (7%). The prevalence of diabetes was highest in Latinas, African Americans, and Native Hawaiians (15%) and lower in Whites (6%) and Japanese Americans (9%).

Table 1.

Age-standardized distribution of hormone-related factors measured at baseline by race/ethnicity in the Multiethnic Cohort Study.

OverallWhiteAfrican AmericanNative HawaiianJapanese AmericanLatina
Total number 91,625 21,742 17,870 6,789 25,028 20,196 
Age at cohort entry (years)a,b 60 (52, 67) 58 (50, 66) 61 (53, 69) 54 (48, 63) 62 (52, 69) 59 (53, 65) 
Duration of follow-up (years)b 21 (18, 22) 21 (17, 21) 21 (14, 22) 20 (14, 21) 21 (20, 21) 21 (19, 22) 
Parity (%) 
 Nulliparous 12 16 12 14 
 Parous 87 84 87 92 86 92 
 1 child 11 12 15 12 
 2 children 23 26 20 15 32 15 
 3 children 20 21 17 18 24 18 
 ≥4 children 32 24 35 53 18 50 
Age at menarche (%) 
 <13 years 48 49 48 54 49 46 
 13–14 years 38 40 36 33 38 38 
 ≥15 years 12 11 13 11 12 14 
Postmenopausal (%) 83 84 84 82 80 84 
Cumulative ovulatory years (%)c 
 Tertile 1: 4–29 years 33 36 41 34 24 38 
 Tertile 2: 30–34 years 34 33 32 35 34 37 
 Tertile 3: 35–45 years 33 32 28 31 42 25 
Age at natural menopause (%)d 
 <45 years 16 14 20 19 11 22 
 45-49 years 31 33 32 31 27 35 
 50-54 years 41 41 36 37 48 35 
 ≥55 years 11 11 11 12 13 
OC use (%) 
 Never 55 48 51 61 61 57 
 Ever 41 50 44 35 36 35 
 <5 years 25 29 26 23 24 24 
 ≥5 years 15 21 18 12 12 10 
PMH use (%)e 
 Never 51 41 61 59 47 56 
 Ever 46 57 35 38 51 39 
 <5 years 30 33 25 28 32 28 
 ≥5 years 15 24 10 18 
Hysterectomy - yes (%) 21 22 30 22 14 21 
Body mass index (%) 
 <25 kg/m2 45 53 24 32 68 32 
 25–29.9 kg/m2 31 28 35 32 24 39 
 ≥30 kg/m2 22 18 37 32 27 
Diabetes - yes (%) 11 15 15 15 
Ever smoker (%) 43 55 53 54 32 33 
Family history of breast or ovarian cancer (%) 14 16 15 18 13 12 
OverallWhiteAfrican AmericanNative HawaiianJapanese AmericanLatina
Total number 91,625 21,742 17,870 6,789 25,028 20,196 
Age at cohort entry (years)a,b 60 (52, 67) 58 (50, 66) 61 (53, 69) 54 (48, 63) 62 (52, 69) 59 (53, 65) 
Duration of follow-up (years)b 21 (18, 22) 21 (17, 21) 21 (14, 22) 20 (14, 21) 21 (20, 21) 21 (19, 22) 
Parity (%) 
 Nulliparous 12 16 12 14 
 Parous 87 84 87 92 86 92 
 1 child 11 12 15 12 
 2 children 23 26 20 15 32 15 
 3 children 20 21 17 18 24 18 
 ≥4 children 32 24 35 53 18 50 
Age at menarche (%) 
 <13 years 48 49 48 54 49 46 
 13–14 years 38 40 36 33 38 38 
 ≥15 years 12 11 13 11 12 14 
Postmenopausal (%) 83 84 84 82 80 84 
Cumulative ovulatory years (%)c 
 Tertile 1: 4–29 years 33 36 41 34 24 38 
 Tertile 2: 30–34 years 34 33 32 35 34 37 
 Tertile 3: 35–45 years 33 32 28 31 42 25 
Age at natural menopause (%)d 
 <45 years 16 14 20 19 11 22 
 45-49 years 31 33 32 31 27 35 
 50-54 years 41 41 36 37 48 35 
 ≥55 years 11 11 11 12 13 
OC use (%) 
 Never 55 48 51 61 61 57 
 Ever 41 50 44 35 36 35 
 <5 years 25 29 26 23 24 24 
 ≥5 years 15 21 18 12 12 10 
PMH use (%)e 
 Never 51 41 61 59 47 56 
 Ever 46 57 35 38 51 39 
 <5 years 30 33 25 28 32 28 
 ≥5 years 15 24 10 18 
Hysterectomy - yes (%) 21 22 30 22 14 21 
Body mass index (%) 
 <25 kg/m2 45 53 24 32 68 32 
 25–29.9 kg/m2 31 28 35 32 24 39 
 ≥30 kg/m2 22 18 37 32 27 
Diabetes - yes (%) 11 15 15 15 
Ever smoker (%) 43 55 53 54 32 33 
Family history of breast or ovarian cancer (%) 14 16 15 18 13 12 

aNot age-standardized.

bValues are median (P25, P75).

cAmong 63,107 women with available information. Calculated as years between ages at menarche and natural menopause (if postmenopausal) or baseline (if premenopausal), minus the duration of pregnancies and OC use.

dAmong 51,164 postmenopausal women who reported a natural menopause.

eAmong 75,768 postmenopausal women. Percentages may not add up to 100% due to missing data.

During a median follow-up of 21 (interquartile range, 18–22) years, 607 incident EOC cases were identified, of which 155 occurred in Whites, 93 in African Americans, 57 in Native Hawaiians, 161 in Japanese Americans, and 141 in Latinas. Age-standardized histologic subtype and stage distributions varied by racial/ethnic group (Table 2). The proportion of serous tumors was highest in Whites (78%) followed by African Americans (76%), Native Hawaiians (73%), Latinas (69%), and Japanese Americans (67%). The proportion of endometrioid tumors was highest in Japanese Americans (15%), followed by Latinas and African Americans (11%), and was lowest in Whites (7%) and Native Hawaiians (3%). Japanese Americans had a high proportion of clear cell tumors (8% vs. 3%–6% in the other groups) and Native Hawaiians had a high proportion of mucinous tumors (13% vs. 1%–6% in other groups). Japanese Americans had the lowest frequency of distant disease (62% vs. 74%–78% in the other groups).

Table 2.

Age-standardized distribution of EOC case characteristics by race/ethnicity.

OverallWhiteAfrican AmericanNative HawaiianJapanese AmericanLatina
Number of EOC cases 607 155 93 57 161 141 
Age at diagnosis (years)a,b 71 (64, 78) 70 (63, 77) 72 (63, 78) 68 (63, 74) 72 (64, 79) 69 (65, 75) 
Duration of follow-up (years)b,c 10 (5, 15) 9 (4, 15) 9 (5, 14) 11 (4, 15) 9 (5, 14) 9 (4, 15) 
Histologic subtype (%) 
 Serousd 74 78 76 73 67 69 
 Endometrioid 11 15 11 
 Clear cell 
 Mucinous 13 
 Carcinosarcoma & other 
Disease stagee (%) 
 Localized and regional 24 21 19 21 38 21 
 Distant 73 78 76 77 62 74 
OverallWhiteAfrican AmericanNative HawaiianJapanese AmericanLatina
Number of EOC cases 607 155 93 57 161 141 
Age at diagnosis (years)a,b 71 (64, 78) 70 (63, 77) 72 (63, 78) 68 (63, 74) 72 (64, 79) 69 (65, 75) 
Duration of follow-up (years)b,c 10 (5, 15) 9 (4, 15) 9 (5, 14) 11 (4, 15) 9 (5, 14) 9 (4, 15) 
Histologic subtype (%) 
 Serousd 74 78 76 73 67 69 
 Endometrioid 11 15 11 
 Clear cell 
 Mucinous 13 
 Carcinosarcoma & other 
Disease stagee (%) 
 Localized and regional 24 21 19 21 38 21 
 Distant 73 78 76 77 62 74 

aNot age-standardized.

bValues are median (P25, P75).

cTime between cohort entry and diagnosis.

dCombined serous and carcinoma not otherwise specified histologic subtype.

eThree percent of missing data in overall population (0%–6% in racial/ethnic groups). Percentages may not add up to 100% due to missing data.

Compared with Whites, African Americans had a lower age-adjusted EOC risk (HR = 0.74; CI, 0.57–0.96; Table 3). We observed similar risk estimates after additional adjustment for menopausal status, parity, and OC use; relative to Whites, multivariable adjusted EOC risk was lower in African Americans (HR = 0.74; CI, 0.57–0.97) and Japanese Americans (HR = 0.79; CI, 0.63–0.99) and was suggestively higher in Native Hawaiians (HR = 1.36; CI, 0.99–1.85). EOC risk in Latinas did not differ from that in Whites (multivariable adjusted HR = 0.96; CI, 0.76–1.22). Further comprehensive adjustment for all EOC risk factors in a fully adjusted model did not change these results. Associations between race/ethnicity and EOC risk were similar in analyses restricted to postmenopausal women and to serous EOC.

Table 3.

Associations (HR and 95% CI) between race/ethnicity and EOC risk in the overall study population, as well as restricting to postmenopausal women at baseline and to serous EOC.

nn casesAge-adjustedMultivariable adjustedaFully adjusteda,b
Total EOC 
 White (ref.) 21,742 155 1.00 1.00 1.00 
 African American 17,870 93 0.74 (0.57–0.96) 0.74 (0.57–0.97) 0.77 (0.59–1.01) 
 Native Hawaiian 6,789 57 1.30 (0.96–1.76) 1.36 (0.99–1.85) 1.34 (0.98–1.84) 
 Japanese American 25,028 161 0.83 (0.66–1.03) 0.79 (0.63–0.99) 0.79 (0.63–1.00) 
 Latina 20,196 141 0.93 (0.74–1.17) 0.96 (0.76–1.22) 1.02 (0.80–1.30) 
Postmenopausal women 
 White (ref.) 17,590 132 1.00 1.00 1.00 
 African American 15,350 83 0.74 (0.57–0.98) 0.75 (0.57–0.99) 0.78 (0.58–1.04) 
 Native Hawaiian 4,932 45 1.31 (0.94–1.84) 1.37 (0.97–1.93) 1.36 (0.96–1.93) 
 Japanese American 20,471 138 0.82 (0.65–1.04) 0.79 (0.62–1.00) 0.79 (0.61–1.01) 
 Latina 17,425 122 0.90 (0.70–1.15) 0.93 (0.72–1.20) 1.00 (0.77–1.30) 
Serous EOCc 
 White (ref.) 21,742 122 1.00 1.00 1.00 
 African American 17,870 71 0.70 (0.52–0.94) 0.70 (0.52–0.94) 0.75 (0.55–1.03) 
 Native Hawaiian 6,789 42 1.25 (0.88–1.78) 1.27 (0.89–1.82) 1.30 (0.90–1.87) 
 Japanese American 25,028 113 0.72 (0.56–0.93) 0.69 (0.53–0.89) 0.67 (0.51–0.87) 
 Latina 20,196 99 0.83 (0.63–1.08) 0.83 (0.63–1.10) 0.89 (0.67–1.18) 
nn casesAge-adjustedMultivariable adjustedaFully adjusteda,b
Total EOC 
 White (ref.) 21,742 155 1.00 1.00 1.00 
 African American 17,870 93 0.74 (0.57–0.96) 0.74 (0.57–0.97) 0.77 (0.59–1.01) 
 Native Hawaiian 6,789 57 1.30 (0.96–1.76) 1.36 (0.99–1.85) 1.34 (0.98–1.84) 
 Japanese American 25,028 161 0.83 (0.66–1.03) 0.79 (0.63–0.99) 0.79 (0.63–1.00) 
 Latina 20,196 141 0.93 (0.74–1.17) 0.96 (0.76–1.22) 1.02 (0.80–1.30) 
Postmenopausal women 
 White (ref.) 17,590 132 1.00 1.00 1.00 
 African American 15,350 83 0.74 (0.57–0.98) 0.75 (0.57–0.99) 0.78 (0.58–1.04) 
 Native Hawaiian 4,932 45 1.31 (0.94–1.84) 1.37 (0.97–1.93) 1.36 (0.96–1.93) 
 Japanese American 20,471 138 0.82 (0.65–1.04) 0.79 (0.62–1.00) 0.79 (0.61–1.01) 
 Latina 17,425 122 0.90 (0.70–1.15) 0.93 (0.72–1.20) 1.00 (0.77–1.30) 
Serous EOCc 
 White (ref.) 21,742 122 1.00 1.00 1.00 
 African American 17,870 71 0.70 (0.52–0.94) 0.70 (0.52–0.94) 0.75 (0.55–1.03) 
 Native Hawaiian 6,789 42 1.25 (0.88–1.78) 1.27 (0.89–1.82) 1.30 (0.90–1.87) 
 Japanese American 25,028 113 0.72 (0.56–0.93) 0.69 (0.53–0.89) 0.67 (0.51–0.87) 
 Latina 20,196 99 0.83 (0.63–1.08) 0.83 (0.63–1.10) 0.89 (0.67–1.18) 

aCox proportional hazards models adjusted for baseline age (continuous) and menopausal status [pre-/peri- (ref.), postmenopausal], use of OCs [never (ref.), ever], and number of children [0 (ref.), 1, 2, 3, ≥4].

bModels additionally adjusted for age at menarche [<13 (ref.), 13–14, ≥15 years], age at natural menopause [if postmenopausal; <44 (ref.), 45–49, 50–54, ≥55 years, surgical or unknown type of menopause], duration of PMH use [if postmenopausal; never (ref.), <5, ≥5 years], duration of OC use [never (ref.), <5, ≥5 years], hysterectomy [no (ref.), yes], family history of breast and/or ovarian cancer [no (ref.), yes, missing], diabetes [no (ref.), yes], and smoking status [never (ref.), ever].

cSerous/carcinoma not otherwise specified histologic subtype.

Table 4 shows associations between hormone-related factors and EOC risk in the overall population and for each of the racial/ethnic groups. In the overall study population, parity and OC use were inversely associated with EOC risk (parous vs. nulliparous: HR = 0.72; CI, 0.58–0.89; ≥4 children vs. nulliparous: HR = 0.62; CI, 0.48–0.81; ever vs. never OC use: HR = 0.77; CI, 0.63; 0.94; ≥5 years vs. never OC use: HR = 0.54; CI, 0.39–0.73). We found no statistically significant interaction with race/ethnicity for any of the hormone-related factors (Pint ≥ 0.18). HRs for parity (vs. nulliparity) ranged from 0.64 to 0.82 across racial/ethnic groups, but the association was significant only for Japanese Americans (HR = 0.64; CI, 0.43–0.94) among whom there were additional reductions in risk with an increasing number of children (e.g., ≥4 vs. 0 children: HR = 0.45; CI, 0.26–0.79; Ptrend < 0.01). The inverse association between ever use of OCs and EOC risk was observed in most racial/ethnic groups (HRs ranged from 0.60 to 0.77) except for Whites; this association was significant only among Japanese Americans (HR = 0.60; CI, 0.39–0.93) and stronger associations were observed with increasing duration of OC use in this group (≥5 years vs. never OC use: HR = 0.35; CI, 0.16–0.78). Age at natural menopause and PMH use were not associated with EOC risk in the overall population and there was no interaction with race/ethnicity (Pint ≥ 0.18). However, risk of EOC among Latinas increased with a later age at natural menopause (≥55 vs. <45 years: HR = 2.60; CI, 1.24–5.42). Compared with Latinas who never used PMH, ever use of PMH was positively associated with EOC risk (HR = 1.46; CI, 1.02–2.10) and the association strengthened with a longer duration of use (≥5 years vs. never: HR = 2.13; CI, 1.30–3.49). Cumulative ovulatory years were suggestively associated with EOC risk in the overall population (tertile 3 vs. 1: HR = 1.27; 0.96–1.67; Ptrend = 0.01; Pint race/ethnicity = 0.37), although there was a suggestive trend in Native Hawaiians (0.09) and Latinas (0.08), no significant associations were seen in any racial/ethnic group. There were no associations for age at menarche, obesity, smoking status, or diabetes with EOC risk among the overall population or in any of the racial/ethnic groups.

Table 4.

Associations (HR and 95% CI)a between hormone-related factors and EOC risk by race/ethnicity.

OverallbWhiteAfrican AmericanNative HawaiianJapanese AmericanLatinaPintc
Number of cases/total number 607/91,625 155/21,742 93/17,870 57/6,789 161/25,028 141/20,196  
Parity 
 Nulliparous (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Parous 0.72 (0.58–0.89) 0.70 (0.47–1.03) 0.82 (0.46–1.45) 0.77 (0.33–1.84) 0.64 (0.43–0.94) 0.82 (0.47–1.44) 0.89d 
 1 child 0.82 (0.61–1.12) 1.01 (0.60–1.71) 0.54 (0.23–1.25) 0.43 (0.09–2.16) 0.85 (0.49–1.46) 0.96 (0.43–2.11)  
 2 children 0.78 (0.60–1.01) 0.67 (0.41–1.07) 0.93 (0.46–1.84) 0.84 (0.29–2.39) 0.72 (0.46–1.12) 1.00 (0.51–1.96)  
 3 children 0.74 (0.56–0.97) 0.55 (0.33–0.94) 1.20 (0.61–2.36) 0.83 (0.30–2.27) 0.59 (0.36–0.96) 1.00 (0.53–1.91)  
 ≥4 children 0.62 (0.48–0.81) 0.69 (0.43–1.12) 0.66 (0.34–1.27) 0.80 (0.32–1.96) 0.45 (0.26–0.79) 0.71 (0.40–1.28) 0.43e 
Ptrend number of children (incl. 0) <0.01 0.08 0.64 0.78 <0.01 0.02  
Ptrend number of children (excl. 0) 0.01 0.34 0.92 0.49 0.03 0.01  
Age at menarche 
 <13 years (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 13–14 years 0.83 (0.70–0.99) 0.98 (0.70–1.39) 0.72 (0.45–1.15) 0.86 (0.48–1.55) 0.74 (0.52–1.05) 0.84 (0.59–1.21)  
 ≥15 years 1.01 (0.79–1.29) 1.50 (0.95–2.39) 0.81 (0.42–1.56) 0.92 (0.39–2.21) 0.98 (0.62–1.55) 0.80 (0.48–1.35) 0.89 
Age at natural menopausef 
 <45 years (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 45–49 years 1.04 (0.75–1.44) 0.96 (0.52–1.76) 1.56 (0.60–4.03) 0.72 (0.22–2.36) 0.91 (0.47–1.74) 1.03 (0.53–1.99)  
 50–54 years 1.10 (0.80–1.51) 0.83 (0.46–1.52) 1.88 (0.75–4.69) 1.66 (0.61–4.56) 0.84 (0.45–1.55) 1.16 (0.61–2.20)  
 ≥55 years 1.25 (0.84–1.86) 1.00 (0.47–2.16) 0.76 (0.19–3.09) 0.67 (0.13–3.54) 0.99 (0.47–2.07) 2.60 (1.24–5.42) 0.18 
Cumulative ovulatory yearsg 
 Tertile 1 (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Tertile 2 1.06 (0.81–1.38) 1.18 (0.72–1.94) 1.04 (0.48–2.23) 2.14 (0.84–5.46) 0.74 (0.44–1.23) 0.98 (0.55–1.74)  
 Tertile 3 1.27 (0.96–1.67) 1.25 (0.73–2.13) 1.39 (0.63–3.04) 2.57 (0.95–6.96) 0.80 (0.48–1.33) 1.64 (0.93–2.91) 0.37 
Ptrend 0.01 0.25 0.31 0.09 0.64 0.08  
OC use 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 0.77 (0.63–0.94) 1.13 (0.78–1.66) 0.77 (0.46–1.30) 0.62 (0.33–1.17) 0.60 (0.39–0.93) 0.69 (0.46–1.04) 0.67h 
 Ever <5 years 0.91 (0.73–1.13) 1.43 (0.96–2.14) 0.88 (0.49–1.56) 0.76 (0.39–1.50) 0.75 (0.47–1.18) 0.71 (0.45–1.13)  
 Ever ≥5 years 0.54 (0.39–0.73) 0.66 (0.38–1.14) 0.66 (0.32–1.35) 0.38 (0.13–1.11) 0.35 (0.16–0.78) 0.65 (0.34–1.25) 0.63i 
PMH usej 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 1.08 (0.91–1.29) 0.92 (0.65–1.31) 0.82 (0.51–1.30) 0.92 (0.50–1.69) 1.21 (0.86–1.70) 1.46 (1.02–2.10) 0.25h 
 Ever <5 years 1.05 (0.86–1.29) 0.82 (0.54–1.26) 0.85 (0.51–1.42) 0.97 (0.50–1.87) 1.30 (0.88–1.91) 1.31 (0.87–1.98)  
 Ever ≥5 years 1.16 (0.91–1.48) 1.04 (0.68–1.59) 0.59 (0.24–1.48) 0.83 (0.29–2.40) 1.11 (0.70–1.76) 2.13 (1.30–3.49) 0.18i 
Hysterectomyk 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.02 (0.83–1.25) 1.09 (0.73–1.62) 1.16 (0.74–1.83) 1.13 (0.60–2.13) 0.77 (0.48–1.24) 1.00 (0.67–1.52) 0.73 
BMI 
 <25 kg/m2 (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 25–29.9 kg/m2 0.77 (0.63–0.94) 0.83 (0.56–1.21) 0.81 (0.46–1.43) 0.48 (0.24–0.95) 0.87 (0.59–1.27) 0.75 (0.50–1.13)  
 ≥30 kg/m2 1.12 (0.90–1.39) 1.12 (0.74–1.70) 1.37 (0.81–2.29) 0.76 (0.42–1.40) 1.03 (0.54–1.97) 1.10 (0.73–1.66) 0.94 
Ptrend 0.16 0.23 0.52 0.64 0.82 0.40  
Diabetes 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.12 (0.86–1.45) 0.98 (0.46–2.10) 1.38 (0.80–2.39) 1.70 (0.87–3.30) 0.72 (0.38–1.36) 1.16 (0.72–1.85) 0.40 
Smoking status 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 1.07 (0.90,1.26) 1.08 (0.79–1.49) 0.86 (0.57–1.30) 0.77 (0.45–1.29) 1.20 (0.86–1.68) 1.25 (0.88–1.77) 0.42 
Family history of breast and/or ovarian cancer 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.19 (0.96–1.48) 1.08 (0.71–1.65) 1.08 (0.62–1.90) 0.82 (0.38–1.73) 1.36 (0.90–2.05) 1.48 (0.95–2.31) 0.63 
OverallbWhiteAfrican AmericanNative HawaiianJapanese AmericanLatinaPintc
Number of cases/total number 607/91,625 155/21,742 93/17,870 57/6,789 161/25,028 141/20,196  
Parity 
 Nulliparous (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Parous 0.72 (0.58–0.89) 0.70 (0.47–1.03) 0.82 (0.46–1.45) 0.77 (0.33–1.84) 0.64 (0.43–0.94) 0.82 (0.47–1.44) 0.89d 
 1 child 0.82 (0.61–1.12) 1.01 (0.60–1.71) 0.54 (0.23–1.25) 0.43 (0.09–2.16) 0.85 (0.49–1.46) 0.96 (0.43–2.11)  
 2 children 0.78 (0.60–1.01) 0.67 (0.41–1.07) 0.93 (0.46–1.84) 0.84 (0.29–2.39) 0.72 (0.46–1.12) 1.00 (0.51–1.96)  
 3 children 0.74 (0.56–0.97) 0.55 (0.33–0.94) 1.20 (0.61–2.36) 0.83 (0.30–2.27) 0.59 (0.36–0.96) 1.00 (0.53–1.91)  
 ≥4 children 0.62 (0.48–0.81) 0.69 (0.43–1.12) 0.66 (0.34–1.27) 0.80 (0.32–1.96) 0.45 (0.26–0.79) 0.71 (0.40–1.28) 0.43e 
Ptrend number of children (incl. 0) <0.01 0.08 0.64 0.78 <0.01 0.02  
Ptrend number of children (excl. 0) 0.01 0.34 0.92 0.49 0.03 0.01  
Age at menarche 
 <13 years (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 13–14 years 0.83 (0.70–0.99) 0.98 (0.70–1.39) 0.72 (0.45–1.15) 0.86 (0.48–1.55) 0.74 (0.52–1.05) 0.84 (0.59–1.21)  
 ≥15 years 1.01 (0.79–1.29) 1.50 (0.95–2.39) 0.81 (0.42–1.56) 0.92 (0.39–2.21) 0.98 (0.62–1.55) 0.80 (0.48–1.35) 0.89 
Age at natural menopausef 
 <45 years (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 45–49 years 1.04 (0.75–1.44) 0.96 (0.52–1.76) 1.56 (0.60–4.03) 0.72 (0.22–2.36) 0.91 (0.47–1.74) 1.03 (0.53–1.99)  
 50–54 years 1.10 (0.80–1.51) 0.83 (0.46–1.52) 1.88 (0.75–4.69) 1.66 (0.61–4.56) 0.84 (0.45–1.55) 1.16 (0.61–2.20)  
 ≥55 years 1.25 (0.84–1.86) 1.00 (0.47–2.16) 0.76 (0.19–3.09) 0.67 (0.13–3.54) 0.99 (0.47–2.07) 2.60 (1.24–5.42) 0.18 
Cumulative ovulatory yearsg 
 Tertile 1 (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Tertile 2 1.06 (0.81–1.38) 1.18 (0.72–1.94) 1.04 (0.48–2.23) 2.14 (0.84–5.46) 0.74 (0.44–1.23) 0.98 (0.55–1.74)  
 Tertile 3 1.27 (0.96–1.67) 1.25 (0.73–2.13) 1.39 (0.63–3.04) 2.57 (0.95–6.96) 0.80 (0.48–1.33) 1.64 (0.93–2.91) 0.37 
Ptrend 0.01 0.25 0.31 0.09 0.64 0.08  
OC use 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 0.77 (0.63–0.94) 1.13 (0.78–1.66) 0.77 (0.46–1.30) 0.62 (0.33–1.17) 0.60 (0.39–0.93) 0.69 (0.46–1.04) 0.67h 
 Ever <5 years 0.91 (0.73–1.13) 1.43 (0.96–2.14) 0.88 (0.49–1.56) 0.76 (0.39–1.50) 0.75 (0.47–1.18) 0.71 (0.45–1.13)  
 Ever ≥5 years 0.54 (0.39–0.73) 0.66 (0.38–1.14) 0.66 (0.32–1.35) 0.38 (0.13–1.11) 0.35 (0.16–0.78) 0.65 (0.34–1.25) 0.63i 
PMH usej 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 1.08 (0.91–1.29) 0.92 (0.65–1.31) 0.82 (0.51–1.30) 0.92 (0.50–1.69) 1.21 (0.86–1.70) 1.46 (1.02–2.10) 0.25h 
 Ever <5 years 1.05 (0.86–1.29) 0.82 (0.54–1.26) 0.85 (0.51–1.42) 0.97 (0.50–1.87) 1.30 (0.88–1.91) 1.31 (0.87–1.98)  
 Ever ≥5 years 1.16 (0.91–1.48) 1.04 (0.68–1.59) 0.59 (0.24–1.48) 0.83 (0.29–2.40) 1.11 (0.70–1.76) 2.13 (1.30–3.49) 0.18i 
Hysterectomyk 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.02 (0.83–1.25) 1.09 (0.73–1.62) 1.16 (0.74–1.83) 1.13 (0.60–2.13) 0.77 (0.48–1.24) 1.00 (0.67–1.52) 0.73 
BMI 
 <25 kg/m2 (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 25–29.9 kg/m2 0.77 (0.63–0.94) 0.83 (0.56–1.21) 0.81 (0.46–1.43) 0.48 (0.24–0.95) 0.87 (0.59–1.27) 0.75 (0.50–1.13)  
 ≥30 kg/m2 1.12 (0.90–1.39) 1.12 (0.74–1.70) 1.37 (0.81–2.29) 0.76 (0.42–1.40) 1.03 (0.54–1.97) 1.10 (0.73–1.66) 0.94 
Ptrend 0.16 0.23 0.52 0.64 0.82 0.40  
Diabetes 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.12 (0.86–1.45) 0.98 (0.46–2.10) 1.38 (0.80–2.39) 1.70 (0.87–3.30) 0.72 (0.38–1.36) 1.16 (0.72–1.85) 0.40 
Smoking status 
 Never (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Ever 1.07 (0.90,1.26) 1.08 (0.79–1.49) 0.86 (0.57–1.30) 0.77 (0.45–1.29) 1.20 (0.86–1.68) 1.25 (0.88–1.77) 0.42 
Family history of breast and/or ovarian cancer 
 No (ref.) 1.00 1.00 1.00 1.00 1.00 1.00  
 Yes 1.19 (0.96–1.48) 1.08 (0.71–1.65) 1.08 (0.62–1.90) 0.82 (0.38–1.73) 1.36 (0.90–2.05) 1.48 (0.95–2.31) 0.63 

aCox proportional hazards models adjusted for baseline age (continuous), menopausal status [pre-/peri- (ref.), postmenopausal], use of OCs [never (ref.), ever], and number of children [0 (ref.), 1, 2, 3, ≥4].

bModels in the full cohort additionally adjusted for race/ethnicity [White (ref.), African American, Native Hawaiian, Japanese American, Latina].

cPinteraction comparing models without with models with interaction terms for the exposure and race/ethnicity variables using log-likelihood ratio tests.

dParity (no, yes).

eNumber of children (0, 1, 2, 3, ≥4).

fAmong 51,164 postmenopausal women with a natural menopause.

gAmong 63,107 women with available information.

hNever versus ever use.

iDuration of use (never, <5, ≥5 years).

jAmong 75,768 postmenopausal women.

kAdditionally adjusted for ever PMH use [if postmenopausal; never (ref), ever].

We observed no interaction between menopausal status and race/ethnicity (Pint = 0.96). When restricting analyses to postmenopausal women (n = 520 cases), we observed similar results to the overall population (Supplementary Table S2). In analyses focusing on the serous histologic subtype (n = 447 cases), associations with hormone-related factors were generally similar to those for total EOC, with the exception of OC use where there was a significant protective association with longer duration of use in Whites (≥5 years vs. never use: HR = 0.50; CI, 0.26–0.98; Supplementary Table S3). The association for OC use with risk of serous tumors was stronger for Japanese Americans (≥5 years vs. never OC use HR = 0.08; CI, 0.01–0.56) than in analyses of total EOC. Associations observed between PMH use and total EOC among Latinas were attenuated when restricting to serous EOC (≥5 years vs. never PMH use: HR = 1.61; CI, 0.84–3.06).

We performed a comprehensive prospective analysis and compared EOC risk in a large population of White, African American, Native Hawaiian, Japanese American, and Latina women. Risk of EOC was comparable in Whites and Latinas, but we observed suggestively higher EOC risk in Native Hawaiians and lower EOC risk in African Americans and Japanese Americans. These differences were not fully explained by hormone-related risk factors. Although we found no statistically significant interaction between race/ethnicity, selected hormone-related factors were most strongly associated with EOC risk in Japanese Americans and Latinas.

Our finding of similar EOC risk in Whites and Latinas, and lower EOC risk in African Americans and Japanese Americans than in Whites, is in agreement with U.S. nationwide statistics (1, 16). We observed a suggestive higher EOC risk in Native Hawaiians relative to Whites, whereas the Hawaii Tumor Registry reported similar age-adjusted incidence rates for both groups (2). The racial/ethnic differences in EOC risk observed in our study were not fully explained by hormone-related factors. This is in line with previous studies that found that reproductive and lifestyle factors explained only a small proportion of the EOC risk differences between Whites and African Americans (7, 10) and between Whites and Latinas (7).

In the pooled OCAC study, interactions with race/ethnicity were observed in associations of parity, OC use, hysterectomy, and family history of breast and ovarian cancer with EOC risk (6). There were no statistically significant interactions between race/ethnicity and any of the hormone-related EOC risk factors that we evaluated in this study, which may be related to the modest sample size. We did however observe strong inverse associations for parity and OC use with EOC risk among Japanese Americans. This finding is consistent with strong protective associations reported for parity and OC use with EOC risk among Asian/Pacific Islanders in the OCAC study (6). In contrast to the OCAC report and the Ovarian Cancer Cohort Consortium (OC3) in (mostly) White women (17), family history of breast/ovarian cancer was not associated with EOC risk in our overall study population or in any of the racial/ethnic groups. Hysterectomy was not associated with EOC risk in our study; OC3 similarly reported no association, but OCAC reported a positive association (6, 17). Compared with never use of PMH, we observed that both ever-use of PMH and a longer duration (≥5 years) of PMH use were associated with an increased EOC risk specifically among Latinas. The only previous study to evaluate associations between PMH use and EOC risk in Latinas found no association in Latinas or in other racial/ethnic groups (6). The positive association with PMH use is however consistent with the higher risk with PMH use that has been reported in a pooled analysis of 22 prospective cohort studies (based mostly on White women) in the OC3 (17). Interestingly, we also observed that having a later age at menopause was associated with an increased EOC risk among Latinas. To our knowledge, previous studies have not evaluated age at menopause as an EOC risk factor in Latinas specifically, but a small positive association between having a later age at menopause and EOC risk has been reported in the OC3 study (17). It will be of interest to further investigate PMH use and age at natural menopause as EOC risk factors among Latinas. Our finding of increasing risk with a longer cumulative duration of ovulatory cycles is in line with previous studies in Mexican women (18) and in (mostly) White women (19–21). To our knowledge, previous studies have not reported on hormone-related risk factors in relation to EOC risk in Native Hawaiians specifically. Our study highlighted a suggestive 36% increase in EOC risk among Native Hawaiians compared with Whites, and demonstrates the need for larger studies of Native Hawaiian women to further explore potential reasons for their higher EOC risk.

The strengths of our study include the prospective, ethnically diverse, population-based design of the MEC, which has been shown to be representative of its source populations (13). To our knowledge, this study is the first to evaluate the impact of hormone-related EOC risk factors in Native Hawaiians. Although the MEC is one of the largest cohorts of its kind, EOC remains a rare disease and case numbers were modest, particularly for African Americans and Native Hawaiians. We conducted a sensitivity analysis of serous EOC, the most common EOC subtype (22), and observed broadly similar findings to analyses of total EOC. Case numbers were limited to investigate racial/ethnic differences in nonserous histologic subtypes, as well as premenopausal women at baseline. Another limitation was that the MEC baseline questionnaire did not collect information on breastfeeding, tubal ligation, or endometriosis; therefore, we could not account for these factors in our analysis. Because of multiple comparisons, some of our findings may be due to chance and should be confirmed in additional studies.

Our results suggest that differences in EOC risk among five racial/ethnic groups represented in the MEC Study were not explained by established risk factors, and differences in risk remained. Associations between hormone-related factors and EOC risk did not significantly differ across racial/ethnic groups, although parity and OC use were particularly relevant to risk in Japanese Americans and PMH use and age at menopause in Latinas. Ours is the first prospective study to contribute to a growing body of evidence on racial/ethnic differences in EOC risk factors. It is of interest to carry out additional studies in consortia of prospective studies, such as the OC3, to better understand the factors that contribute toward disparities in risk and improve prevention strategies, particularly for Native Hawaiian, Asian American, and Latina women.

V.W. Setiawan reports grants from NIH during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.

D. Sarink: Data curation, formal analysis, investigation, visualization, methodology, writing–original draft, project administration, writing–review and editing. A.H. Wu: Conceptualization, resources, methodology, writing–review and editing. L. Le Marchand: Conceptualization, resources, data curation, funding acquisition, methodology, writing–review and editing. K.K. White: Resources, data curation, methodology, writing–review and editing. S.-Y. Park: Formal analysis, methodology, writing–review and editing. V.W. Setiawan: Conceptualization, writing–review and editing. B.Y. Hernandez: Conceptualization, data curation, methodology, writing–review and editing. L.R. Wilkens: Conceptualization, data curation, formal analysis, funding acquisition, writing–review and editing. M.A. Merritt: Conceptualization, formal analysis, supervision, methodology, writing–original draft, project administration, writing–review and editing.

The Multiethnic Cohort is supported by NCI grants R37CA54281 (to L.N. Kolonel) and U01CA164973 (to L. Le Marchand).

For information on applications to gain access to data from the Multiethnic Cohort, please see https://www.uhcancercenter.org/for-researchers/mec-data-sharing.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Torre
LA
,
Trabert
B
,
DeSantis
CE
,
Miller
KD
,
Samimi
G
,
Runowicz
CD
, et al
Ovarian cancer statistics, 2018
.
CA Cancer J Clin
2018
;
68
:
284
96
.
2.
Hawaii Tumor Registry
.
Cancer incidence for the state of Hawai‘i, 1978-2012
. 
2015
.
3.
Schuler
S
,
Ponnath
M
,
Engel
J
,
Ortmann
O
. 
Ovarian epithelial tumors and reproductive factors: a systematic review
.
Arch Gynecol Obstet
2013
;
287
:
1187
204
.
4.
Merritt
MA
,
Cramer
DW
. 
Molecular pathogenesis of endometrial and ovarian cancer
.
Cancer Biomark
2010
;
9
:
287
305
.
5.
La Vecchia
C
. 
Ovarian cancer: epidemiology and risk factors
.
Eur J Cancer Prev
2017
;
26
:
55
62
.
6.
Peres
LC
,
Risch
H
,
Terry
KL
,
Webb
PM
,
Goodman
MT
,
Wu
AH
, et al
Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies
.
Int J Epidemiol
2018
;
47
:
460
72
.
7.
Wu
AH
,
Pearce
CL
,
Tseng
C-C
,
Pike
MC
. 
African Americans and hispanics remain at lower risk of ovarian cancer than non-Hispanic whites after considering nongenetic risk factors and oophorectomy rates
.
Cancer Epidemiol Biomarkers Prev
2015
;
24
:
1094
100
.
8.
John
EM
,
Whittemore
AS
,
Harris
R
,
Itnyre
J
. 
Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group
.
J Natl Cancer Inst
1993
;
85
:
142
7
.
9.
Moorman
PG
,
Palmieri
RT
,
Akushevich
L
,
Berchuck
A
,
Schildkraut
JM
. 
Ovarian cancer risk factors in African-American and white women
.
Am J Epidemiol
2009
;
170
:
598
606
.
10.
Ness
RB
,
Grisso
JA
,
Klapper
J
,
Vergona
R
. 
Racial differences in ovarian cancer risk
.
J Natl Med Assoc
2000
;
92
:
176
82
.
11.
Tung
KH
,
Goodman
MT
,
Wu
AH
,
McDuffie
K
,
Wilkens
LR
,
Kolonel
LN
, et al
Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study
.
Am J Epidemiol
2003
;
158
:
629
38
.
12.
Kolonel
LN
,
Henderson
BE
,
Hankin
JH
,
Nomura
AM
,
Wilkens
LR
,
Pike
MC
, et al
A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics
.
Am J Epidemiol
2000
;
151
:
346
57
.
13.
Kolonel
LN
,
Altshuler
D
,
Henderson
BE
. 
The Multiethnic Cohort study: exploring genes, lifestyle and cancer risk
.
Nat Rev Cancer
2004
;
4
:
519
27
.
14.
Greenland
S
. 
Modeling and variable selection in epidemiologic analysis
.
Am J Public Health
1989
;
79
:
340
9
.
15.
Feskanich
D
,
Hankinson
SE
,
Schernhammer
ES
. 
Nightshift work and fracture risk: the Nurses' Health Study
.
Osteoporos Int
2009
;
20
:
537
42
.
16.
Park
HK
,
Ruterbusch
JJ
,
Cote
ML
. 
Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes
.
Cancer Epidemiol Biomarkers Prev
2017
;
26
:
1511
8
.
17.
Wentzensen
N
,
Poole
EM
,
Trabert
B
,
White
E
,
Arslan
AA
,
Patel
AV
, et al
Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium
.
J Clin Oncol
2016
;
34
:
2888
98
.
18.
Salazar-Martinez
E
,
Lazcano-Ponce
EC
,
Lira-Lira
GG
,
Escudero-De los Rios
P
,
Salmeron-Castro
J
,
Hernandez-Avila
M
, et al
Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico
.
Cancer Res
1999
;
59
:
3658
62
.
19.
Merritt
MA
,
De Pari
M
,
Vitonis
AF
,
Titus
LJ
,
Cramer
DW
,
Terry
KL
, et al
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways
.
Hum Reprod
2013
;
28
:
1406
17
.
20.
Fortner
RT
,
Ose
J
,
Merritt
MA
,
Schock
H
,
Tjønneland
A
,
Hansen
L
, et al
Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort
.
Int J Cancer
2015
;
137
:
1196
208
.
21.
Gates
MA
,
Rosner
BA
,
Hecht
JL
,
Tworoger
SS
. 
Risk factors for epithelial ovarian cancer by histologic subtype
.
Am J Epidemiol
2010
;
171
:
45
53
.
22.
Bowtell
DD
. 
The genesis and evolution of high-grade serous ovarian cancer
.
Nat Rev Cancer
2010
;
10
:
803
8
.